Crispr Therapeutics (CRSP) stock is gaining on Tuesday after the FDA granted exagamglogene autotemcel (exa-cel) a rolling review. More
Articles
Why Stocks Could Skyrocket Following the 2022 Midterm Elections
Instead of approaching the 2022 midterm elections with fear, savvy investors should be buying stocks ahead of a major rebound. More
One Analyst Says Lucid (LCID) Stock Could Surge 60% From Here
LCID stock is catching a bid as traders contemplate Lucid potentially taking a bite out of the fast-growing global EV market. More
Will a Housing Market Crash Be Good for U.S. Renters?
New data shows rent prices are beginning to ease just as home prices are starting to fall. Could a housing market crash help renters? More
Aquestive Therapeutics (AQST) Stock Gains on Positive Data for EpiPen Rival
Aquestive Therapeutics (AQST) stock is taking off Tuesday as investors react to positive clinical trial data from the pharmaceutical company. More
Follow the Insider Money Trail and Buy LAZR Stock
Jim Cramer might not be a fan of LAZR stock, but a prominent big-bank analyst sees the light at the end of the car-market tunnel. More
